New drug under watch: Fabhalta's Real-World safety tracked in korea
NCT ID NCT07416162
First seen Feb 19, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This study is a safety check on the drug Fabhalta (iptacopan) for Korean adults with two rare diseases: paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder, and C3 glomerulopathy (C3G), a kidney disease. Researchers will track side effects and lab results from up to 21 patients in real-world clinics. The goal is to confirm the drug's safety and effectiveness outside of controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.